Comparative value-based pricing of an Ebola vaccine in resource-constrained countries based on cost-effectiveness analysis

References

• World Health Organization (WHO). A strategic framework for emergency preparedness. [cited 2021 August 10]. Available from: https://www.who.int/publications-detail-redirect/a-strategic-framework-for-emergency-preparedness.
   Google Scholar
• Quinn SC, Kumar S. Health inequalities and infectious disease epidemics: a challenge for global health security. Biosecur Bioterror. 2014;12(5):263–273.
   PubMedGoogle Scholar
• Claxton K, Briggs A, Buxton MJ, et al. Value-based pricing for NHS drugs: an opportunity not to be missed? BMJ. 2008;336(7638):251–254.
   PubMed Web of Science ®Google Scholar
• Liozu SM. Value-based pricing special issue: editorial. J Revenue Pricing Manag. 2017;16(1):1–3.
   Web of Science ®Google Scholar
• WHO guideline on country pharmaceutical pricing policies. [cited 2022. Apr 17]. Available from: https://www.who.int/publications/i/item/9789240011878.
   Google Scholar
• Prieto-Pinto L, Garzón-Orjuela N, Lasalvia P, et al. International experience in therapeutic value and value-based pricing: a rapid review of the literature. Value Health Reg Issues. 2020;23:37–48.
   PubMedGoogle Scholar
• Garrison LP, Towse A. Value-Based pricing and reimbursement in personalised healthcare: introduction to the basic health economics. JPM. 2017;7(3):10.
   Google Scholar
• Pearson SD, Ollendorf DA, Chapman RH. New cost-effectiveness methods to determine value-based prices for potential cures: what are the options? Value Health. 2019;22(6):656–660.
   PubMed Web of Science ®Google Scholar
• Zheng H, Yin C, Hoang T, et al. Ebolavirus classification based on natural vectors. DNA Cell Biol. 2015;34(6):418–428.
   PubMed Web of Science ®Google Scholar
• Beeching NJ, Fenech M, Houlihan CF. Ebola virus disease. BMJ. 2014;349:g7348.
   PubMed Web of Science ®Google Scholar
• Weyer J, Grobbelaar A, Blumberg L. Ebola virus disease: history, epidemiology and outbreaks. Curr Infect Dis Rep. 2015;17(5):480.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Ebola virus disease. [cited 2021 October 12]. Available from: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease.
   Google Scholar
• UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpile. [cited 2021 October 16]. Available from: https://www.who.int/news/item/12-01-2021-unicef-who-ifrc-and-msf-announce-the-establishment-of-a-global-ebola-vaccine-stockpile.
   Google Scholar
• Obeng-Kusi M, Habila MA, Roe DJ, et al. Economic evaluation using dynamic transition modeling of Ebola virus vaccination in lower-and-middle-income countries. J Med Econ. 2021;24(sup1):1–13.
   PubMed Web of Science ®Google Scholar
• Chowell G, Hengartner NW, Castillo-Chavez C, et al. The basic reproductive number of Ebola and the effects of public health measures: the cases of Congo and Uganda. J Theor Biol. 2004;229(1):119–126.
   PubMed Web of Science ®Google Scholar
• Emerson J, Kim DD. Global Health CEA – DALY calculator. Center for the evaluation of value and risk in health, Tufts Medical Center, Boston, MA.; 2018. [cited 2021 Aug 9]. Available from: http://ghcearegistry.org/orchard/daly-calculator.
   Google Scholar
• Rivers CM, Lofgren ET, Marathe M, et al. Modeling the impact of interventions on an epidemic of Ebola in Sierra Leone and Liberia. PLOS Curr. 2014;6. DOI:10.1371/currents.outbreaks.4d41fe5d6c05e9df30ddce33c66d084c.
   Google Scholar
• Legrand J, Grais RF, Boelle PY, et al. Understanding the dynamics of Ebola epidemics. Epidemiol Infect. 2007;135(4):610–621.
   PubMed Web of Science ®Google Scholar
• US consumer price index: medical care. [cited 2021 September 11]. Available from: https://ycharts.com/indicators/us_consumer_price_index_medical_care.
   Google Scholar
• Vogel G. Rapid test for Ebola now available. Science AAAS. 2015 [cited 2021 Aug 11]. Available from: https://www.sciencemag.org/news/2015/02/rapid-test-ebola-now-available.
   Google Scholar
• GEVIT_guidance_AppendixK.pdf. [cited 2021 August 6]. Available from: https://www.who.int/csr/resources/publications/ebola/GEVIT_guidance_AppendixK.pdf?ua=1.
   Google Scholar
• Ebola-vaccines-prices-11012021.pdf. [cited 2021 August 6]. Available from: https://www.unicef.org/supply/media/6956/file/Ebola-vaccines-prices-11012021.pdf.
   Google Scholar
• Bartsch SM, Gorham K, Lee BY. The cost of an Ebola case. Pathog Glob Health. 2015;109(1):4–9.
   PubMed Web of Science ®Google Scholar
• Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1545–1602.
   PubMed Web of Science ®Google Scholar
• WHO guide for standardization of economic evaluations of immunization programmes. [cited 2022 Apr 30]. Available from: https://apps.who.int/iris/bitstream/handle/10665/329389/WHO-IVB-19.10-eng.pdf.
   Google Scholar
• Danzon P, Towse A, Mestre-Ferrandiz J. Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. 2015;24(3):294–301.
   PubMed Web of Science ®Google Scholar
• Daroudi R, Akbari Sari A, Nahvijou A, et al. Cost per DALY averted in low, middle- and high-income countries: evidence from the global burden of disease study to estimate the cost-effectiveness thresholds. Cost Eff Resour Alloc. 2021;19(1):7.
   PubMed Web of Science ®Google Scholar
• Jit M. Informing global cost-effectiveness thresholds using country investment decisions: human papillomavirus vaccine introductions in 2006-2018. Value Health. 2021;24(1):61–66.
   PubMed Web of Science ®Google Scholar
• Debellut F, Clark A, Pecenka C, et al. Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study. Lancet Global Health. 2019;7(12):e1664–e1674.
   PubMed Web of Science ®Google Scholar
• Lomas J, Claxton K, Ochalek J. Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. Health Policy Plan. 2022;37(1):45–54.
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Truter I, Lubbe MS, et al. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs. J Eval Clin Pract. 2012;18(2):343–351.
   PubMed Web of Science ®Google Scholar
• Kaslow DC. Force of infection: a determinant of vaccine efficacy? NPJ Vaccines. 2021;6(1):1–7.
   PubMed Web of Science ®Google Scholar
• Luyten J, Beutels P. The social value of vaccination programs: beyond cost-effectiveness. Health Aff. 2016;35(2):212–218.
   Web of Science ®Google Scholar
• Delamater PL, Street EJ, Leslie TF, et al. Complexity of the basic reproduction number (R0) – volume 25, number. Emerg Infect Dis. 2019;25(1):1–4.
   PubMed Web of Science ®Google Scholar
• Roberts M, Heesterbeek H. Bluff your way in epidemic models. Trends Microbiol. 1993;1(9):343–348.
   PubMedGoogle Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health. 2009;12(4):409–418.
   PubMed Web of Science ®Google Scholar
• Obeng-Kusi M, Abraham I. Melanoma epidemiology: pivoting to low- and middle-income countries. JAMA Dermatol. 2022;158(5):489–491.
   PubMed Web of Science ®Google Scholar